AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...
Discover the latest AI use cases in healthcare as leaders grapple with implementation and look ahead to future possibilities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback